Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non Arteritic Ischemic Optic Neuropathy
Interventions
dalfampridine, Placebo
Drug
Lead sponsor
Neuro-Ophthalmologic Associates, PC
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced May 22, 2026, 12:04 AM EDT
Conditions
Non Arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg, Sham Injection Procedure
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced May 22, 2026, 12:04 AM EDT
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
ranibizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 22, 2026, 12:04 AM EDT
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced May 22, 2026, 12:04 AM EDT
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
RPh201 Cohort A, Placebo Cohort A, RPh201 Cohort B, Placebo Cohort B
Drug · Other
Lead sponsor
Regenera Pharma Ltd
Industry
Eligibility
50 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced May 22, 2026, 12:04 AM EDT
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
PDE5 Inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Los Altos, California • National City, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced May 22, 2026, 12:04 AM EDT